The role of tumor necrosis factor-α converting enzyme in renal transplant rejection

American Journal of Nephrology

Volumn 32, Issue 4, 2010, Pages 362-368

  Wang, Jun ^a   Li, Zilong ^a   Al Lamki, Rafia ^b   Wang, Juan ^a   Zuo, Nan ^a   Bradley, John R ^b   Wang, Lining ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Renal transplant; Tumor necrosis factor receptors; Tumor necrosis factor converting enzyme

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; KIDNEY GRAFT REJECTION; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ADAM PROTEINS; CELLS, CULTURED; EPITHELIAL CELLS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RECEPTORS, TUMOR NECROSIS FACTOR; UP-REGULATION;

EID: 77956790711     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320467     Document Type: Article

References (25)

1. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008; 214:149-160.
2. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P: TNF receptor type 2mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 1998; 28: 257-263.
3. Edwards DR, Handsley MM, Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-289.
4. Solomon KA, Pesti N, Wu G, Newton RC: Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol 1999; 163:4105-4108.
5. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, Pober JS, Bradley JR: Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003; 278: 21751-2176 0.
6. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117 : 244-279.
7. Wiedmann MW, Mossner J, Baerwald C, Pierer M: TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 20 09; 9: 295-314.
8. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR: Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81 : 1503-1515.
9. Al-Lamki RS, Wang J,Vandenabeele P, Bradley JA, Thiru S, Luo D, Min W, Pober JS, Bradley JR: TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645.
10. Eason JD, Wee S, Kawai T, Hong HZ, Powel-son JA, Widmer MB, Cosimi AB: Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300-305.
11. Noel C, Copin MC, Hazzan M, Labalette M, Susen S, Lelievre G, Dessaint JP: Immuno-modulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. Transplantation 2000; 69:1102-1107.
12. Reddy P, Slack JL, Davis R, Cerretti DP, Koz-losky CJ, Blanton RA, Shows D, Peschon JJ, Black RA: Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000; 275: 14608-14614.
13. Al-Lamki RS, Wang J, Tolkovsky AM, Bradley JA, Griffin JL, Thiru S, Wang EC, Bolton E, Min W, Moore P, Pober JS, Bradley JR: TL1A both promotes and protec ts from rena l inflammation and injury. J Am Soc Nephrol 2008; 19: 953-960.
14. Jones SJ, Ledgerwood EC, Prins JB, Gal-braith J, Johnson DR, Pober JS, Bradley JR: TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999; 162:1042-1048.
15. Fang YH, Joo DJ, Lim BJ, Kim JY, Kim MS, Jeong HJ, Kim YS: AEB-071 versus tacroli-mus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. Transplant Proc 2010; 42:976-979.
16. Sun K, Kiss E, Bedke J, Stojanovic T, Li Y, Gwinner W, Grone HJ: Role of xanthine oxi-doreductase in experimental acute renal-al-lograft rejection. Transplantation 2004; 77: 1683-1692.
17. Seto T, Kamijo S, Wada Y, Yamaura K, Taka-hashi K, Komatsu K, Otsu Y, Terasaki T, Fu-kui D, Amano J, Taniguchi S, Sagara J, Ito K: Upregulation of the apoptosis-related in-flammasome in cardiac allograft rejection. J Heart Lung Transplant 2010; 29:352-359.
18. Müllberg J, Durie FH, Otten-Evans C, Alder-son MR, Rose-John S, Cosman D, Black RA, Mohler KM: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155: 5198-5205.
19. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF: A metallopro-tease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181:1205-1210.
20. Pardo J, Diaz L , Errasti P, Idoate M, de A lava E, Sola I, Lozano L, Panizo A: Mast cells in chronic rejection of human renal allografts. Virchows Arch 2000; 437: 167-172.
21. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11:867-874.
22. Shah BH, Catt KJ: TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. Trends Pharmacol Sci 2006; 27: 235-237.
23. Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, Ozaki S, Asaoka K, Tanaka E, Moriyama K, Matsumoto T: GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009; 114 : 4517-4526.
24. Boutet P, Aguera-Gonzalez S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT, Vales-Gomez M: Cutting edge: the metalloproteinase ADAM17/TNF-al-pha-converting enzyme regulates proteolyt-ic shedding of the MHC class I-related chain B protein. J Immunol 2009; 18 2: 49-53.
25. Murumkar PR, DasGupta S, Chandani SR, Giridhar R, Yadav MR: Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat 2010; 20: 31-57.